Physician profile
Dana Wright
NPI 1801897053
$5,959.73
in general payments reported to CMS, 2019-2025
32 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,571 · 2020: $202 · 2021: $69.16 · 2022: $1,078 · 2023: $1,120 · 2024: $1,160 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,775.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $759.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $439.40 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $284.57 | 2019-2025 | |
| Lilly USA, LLC | $283.77 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $257.90 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $251.70 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.19 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $227.96 | 2019-2025 | |
| Abbvie INC. | $197.09 | 2019-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $185.58 | 2022-2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $164.36 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $156.32 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.14 | 2022-2024 | |
| Amarin Pharma, INC. | $74.16 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $71.82 | 2022 | |
| Sumitomo Pharma America, INC. | $69.60 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $56.23 | 2022 | |
| Corcept Therapeutics | $49.18 | 2019 | |
| Genentech USA, INC. | $46.58 | 2019 | |
| Daiichi Sankyo INC. | $43.86 | 2024 | Injectafer |
| Allergan, INC. | $40.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.12 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $29.23 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Heartflow, INC. | $24.16 | 2024 | |
| Hologic Sales and Service, LLC | $17.63 | 2019 | |
| Merck Sharp & Dohme LLC | $16.93 | 2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Averitas Pharma INC. | $15.98 | 2023 | Qutenza |
| Currax Pharmaceuticals LLC | $15.93 | 2022 | |
| Nevro Corp. | $13.50 | 2023 | Senza |
| Eisai INC. | $13.01 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.